286 Views | 145 Downloads
Sara Gianella, University of California San Diego, 9500 Gilman Drive MC 0679, La Jolla, CA 92093-0679, USA, Tel: (858) 552-8585, ext 7193; Fax: (858) 552-7445; gianella@ucsd.edu.
We are grateful to the study participants and the ASPIRE and A5353 clinical research staff at Northwestern University (Sherrie Wolfe); Emory University (Kishna Outlaw); University of Cincinnati (Eva Whitehead); Cornell (Todd Stroberg); University of California at San Diego (Edward Seefried) whose commitment and cooperation made this study possible.
BOT has served as a paid consultant to ViiV, Gilead, and Janssen and on the Clinical Care Options speakers bureau, and has received grant funding to his institution from ViiV/GlaxoSmithKline (GSK).
VCM, CJF, CAB, TW, have received grant funding for this study to their institutions through Northwestern University from ViiV/GSK.
BB and SG have no conflicts to declare
This work was supported by an Investigator Sponsored Study grant “Virologic Activity of DTG +3TC in the Genital Compartment: Substudy of ASPIRE and A5353” from ViiV Healthcare to Northwestern University.
ViiV Healthcare/GlaxoSmithKline provided funding and study drugs.
Additional support was provided from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701; the San Diego Center for AIDS Research Translational Virology Core (P30AI036214); as well as the Third Coast Center for AIDS Research (P30AI117943); and Emory Center for AIDS Research (P30AI050409).
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.